FCCC LOGO Faculty Publications
Adams GP , McCartney JE , Wolf EJ , Oppermann H , Tai MS , Eisenberg J , Giantonio B , Schultz J , Bookman MA , Laminet AA , Apell G , Stafford WF , Liu S , Huston JS , Houston LL , Weiner LM
Preclinical Studies and Optimization of Specific Tumor Delivery for 741f8 Sfv, an Anti-C-Erbb-2 Single-Chain Species
International Journal of Pharmacognosy. 1995 ;33 :75-91
PMID: ISI:A1995TH49500009   
Back to previous list
Abstract
Single-chain Fv fragments (sFv) that bind tumor-associated antigens exhibit highly specific tumor targeting characteristics, based on studies of intravenous sFv administration to immunodeficient mice bearing human tumor xenografts. These features suggest that sFv may be used as targeting vehicles for diverse agents such as radionuclides, toxins, chemotherapeutic agents, or genes. However, the quantitative tumor retention of sFv molecules is lowered by their fast clearance and rapid dissociation from antigen. We have found that the retention of tumor-specific 741F8 sFv in tumor is an antigen-specific event and not the result of extravascular pooling. We also have produced divalent 741F8 (sFv')(2) species and have examined their pharmacokinetics and biodistribution properties in relevant tumor-bearing scid mice. Finally, we have employed a number of strategies to optimize the tumor-specific retention of radiolabeled sFv molecules; escalations in administered doses, repetitive intravenous bolus administrations, subcutaneous continuous infusions and the use of an alternate labeling system.
Notes
Times Cited: 1 Article S TH495 INT J PHARMACOGN